Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells

Stem Cells and Development

Volumn 20, Issue 12, 2011, Pages 2115-2126

  Kronsteiner, Barbara ^a,b,c   Wolbank, Susanne ^b,c   Peterbauer, Anja ^a,c   Hackl, Christa ^a   Redl, Heinz ^b,c   Van Griensven, Martijn ^b,c   Gabriel, Christian ^a,c  

^a Red Cross Blood Transfusion Service of Upper Austria   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

^c Austrian Cluster for Tissue Regeneration   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PHYTOHEMAGGLUTININ; PROTEINASE INHIBITOR; SERPIN E1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; AMNION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CONTACT; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SURFACE PROPERTY; T LYMPHOCYTE ACTIVATION;

ADIPOSE TISSUE; AMNION; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SEPARATION; CHEMOKINES; COCULTURE TECHNIQUES; DINOPROSTONE; HLA-DR ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MESENCHYMAL STEM CELLS; SOLUBILITY; T-LYMPHOCYTES; UP-REGULATION;

EID: 82455168177     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0031     Document Type: Article

References (58)

1. Bajada S, I Mazakova, JB Richardson and N Ashammakhi2008). Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med 2:169-183.
2. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
3. Schaffler A and C Buchler2007). Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 25:818-827.
4. Uccelli A, L Moretta and V Pistoia2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
5. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, M Remberger, G Dini, RM Egeler, A Bacigalupo, W Fibbe and O Ringden2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
6. Ringden O, M Uzunel, I Rasmusson, M Remberger, B Sundberg, H Lonnies, HU Marschall, A Dlugosz, A Szakos, Z Hassan, B Omazic, J Aschan, L Barkholt and K Le Blanc2006). Mesenchymal stem cells for treatment of therapyresistant graft-versus-host disease. Transplantation 81:1390-1397.
7. Garcia-Olmo D, M Garcia-Arranz, D Herreros, I Pascual, C Peiro and JA Rodriguez-Montes2005). A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416-1423.
8. Weil BR, MC Manukyan, JL Herrmann, AM Abarbanell, JA Poynter, Y Wang and DR Meldrum2010). The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease. J Surg Res 167:78-86.
9. Friedenstein AJ, KV Petrakova, AI Kurolesova and GP Frolova1968). Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6:230-247.
10. Zuk PA, M Zhu, H Mizuno, J Huang, JW Futrell, AJ Katz, P Benhaim, HP Lorenz and MH Hedrick2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211-228.
11. Fukuchi Y, H Nakajima, D Sugiyama, I Hirose, T Kitamura and K Tsuji2004). Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22:649-658.
12. Lee OK, TK Kuo, WM Chen, KD Lee, SL Hsieh and TH Chen2004). Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103:1669-1675.
13. Lama VN, L Smith, L Badri, A Flint, AC Andrei, S Murray, Z Wang, H Liao, GB Toews, PH Krebsbach, M Peters-Golden, DJ Pinsky, FJ Martinez and VJ Thannickal2007). Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest 117:989-996.
14. Bernardo ME, F Locatelli and WE Fibbe2009). Mesenchymal stromal cells. Ann NY Acad Sci 1176:101-117.
15. Selmani Z, A Naji, I Zidi, B Favier, E Gaiffe, L Obert, C Borg, P Saas, P Tiberghien, N Rouas-Freiss, ED Carosella and F Deschaseaux2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3 + regulatory T cells. Stem Cells 26:212-222.
16. Jiang XX, Y Zhang, B Liu, SX Zhang, Y Wu, XD Yu and N Mao2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120-4126.
17. Kronsteiner B, A Peterbauer-Scherb, R Grillari-Voglauer, H Redl, C Gabriel, M van Griensven and S Wolbank2011). Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol 267:30-38.
18. Maggini J, G Mirkin, I Bognanni, J Holmberg, IM Piazzon, I Nepomnaschy, H Costa, C Canones, S Raiden, M Vermeulen and JR Geffner2010). Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 5:e9252.
19. English K, FP Barry and BP Mahon2008). Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 115:50-58.
20. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
21. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
22. Petrini I, S Pacini, M Petrini, R Fazzi, L Trombi and S Galimberti2009). Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Eur J Clin Invest 39:813-818.
23. Prigione I, F Benvenuto, P Bocca, L Battistini, A Uccelli and V Pistoia2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27:693-702.
24. Rasmusson I, O Ringden, B Sundberg and K Le Blanc2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76:1208-1213.
25. English K, JM Ryan, L Tobin, MJ Murphy, FP Barry and BP Mahon2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25(High) forkhead box P3 + regulatory T cells. Clin Exp Immunol 156:149-160.
26. Ghannam S, J Pene, G Torcy-Moquet, C Jorgensen and H Yssel2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302-312.
27. Aggarwal S and MF Pittenger2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
28. Cui L, S Yin, W Liu, N Li, W Zhang and Y Cao2007). Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng 13:1185-1195.
29. Najar M, G Raicevic, HI Boufker, KH Fayyad, BC De, N Meuleman, D Bron, M Toungouz and L Lagneaux2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 264:171-179.
30. English K, FP Barry, CP Field-Corbett and BP Mahon2007). IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110:91-100.
31. Meisel R, A Zibert, M Laryea, U Gobel, W Daubener and D Dilloo2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediatd tryptophan degradation. Blood 103:4619-4621.
32. Ryan JM, F Barry, JM Murphy and BP Mahon2007). Interferon-gamma does not break, but promotes the immunosuppressiv capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
33. Tipnis S, C Viswanathan and AS Majumdar2010). Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 88:795-806.
34. Najar M, G Raicevic, HI Boufker, H Fayyad-Kazan, BC De, N Meuleman, D Bron, M Toungouz and L Lagneaux2010). Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A 16:3537-3546.
35. Nasef A, C Mazurier, S Bouchet, S Francois, A Chapel, D Thierry, NC Gorin and L Fouillard2008). Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 253:16-22.
36. Groh ME, B Maitra, E Szekely and ON Koc2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 33:928-934.
37. Zhukareva V, M Obrocka, JD Houle, I Fischer and B Neuhuber2010). Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli. Cytokine 50:317-321.
38. Sheng H, Y Wang, Y Jin, Q Zhang, Y Zhang, L Wang, B Shen, S Yin, W Liu, L Cui and N Li2008). A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 18:846-857.
39. Klyushnenkova E, JD Mosca, V Zernetkina, MK Majumdar, KJ Beggs, DW Simonetti, RJ Deans and KR McIntosh2005). T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12:47-57.
40. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, F Vinante, P Romagnani, E Maggi, S Romagnani and F Annunziato2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
41. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
42. Renner P, E Eggenhofer, A Rosenauer, FC Popp, JF Steinmann, P Slowik, EK Geissler, P Piso, HJ Schlitt and MH Dahlke2009). Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 41:2607-2611.
43. Wolbank S, A Peterbauer, M Fahrner, S Hennerbichler, M van Griensven, G Stadler, H Redl and C Gabriel2007). Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng 13:1173-1183.
44. Stadler G, S Hennerbichler, A Lindenmair, A Peterbauer, K Hofer, M van Griensven, C Gabriel, H Redl and S Wolbank2008). Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro. Cytotherapy 10:743-752.
45. Campioni D, R Rizzo, M Stignani, L Melchiorri, L Ferrari, S Moretti, A Russo, GP Bagnara, L Bonsi, F Alviano, G Lanzoni, A Cuneo, OR Baricordi and F Lanza2009). A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytom B Clin Cytom 76:225-230.
46. Petroff MG, L Chen, TA Phillips, D Azzola, P Sedlmayr and JS Hunt2003). B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol Reprod 68:1496-1504.
47. Guleria I, A Khosroshahi, MJ Ansari, A Habicht, M Azuma, H Yagita, RJ Noelle, A Coyle, AL Mellor, SJ Khoury andMH Sayegh2005). A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 202:231-237.
48. Bevilacqua MP1993). Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11:767-804.
49. Ren G, X Zhao, L Zhang, J Zhang, A L'Huillier, W Ling, AI Roberts, AD Le, S Shi, C Shao and Y Shi2010). Inflammatory cytokine-induced intercellular adhesion molecule- 1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184:2321-2328.
50. Spaggiari GM, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari and L Moretta2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327-1333.
51. Spaggiari GM, H Abdelrazik, F Becchetti and L Moretta2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576-6583.
52. Wang D, K Chen, WT Du, ZB Han, H Ren, Y Chi, SG Yang, F Bayard, D Zhu and ZC Han2010). CD14 + monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells. Exp Cell Res 316:2414-2423.
53. Le Blanc K, I Rasmusson, C Gotherstrom, C Seidel, B Sundberg, M Sundin, K Rosendahl, C Tammik and O Ringden2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin- activated lymphocytes. Scand J Immunol 60:307-315.
54. Ramasamy R, CK Tong, HF Seow, S Vidyadaran and F Dazzi2008). The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 251:131-136.
55. Sancho D, M Gomez and F Sanchez-Madrid2005). CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 26:136-140.
56. Karlsson H, S Samarasinghe, LM Ball, B Sundberg, AC Lankester, F Dazzi, M Uzunel, K Rao, P Veys, K Le Blanc, O Ringden and PJ Amrolia2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 112:532-541.
57. Rasmusson I, O Ringden, B Sundberg and K Le Blanc2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 305:33-41.
58. Sullivan KE, J Cutilli, LM Piliero, D Ghavimi-Alagha, SE Starr, DE Campbell and SD Douglas2000). Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 7:920-924.